- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07678528
Exposome, Pollutants, Biology in the Older Subject: EXPOSAGE (EXPOSAGE)
24 juni 2026 uppdaterad av: Centre Hospitalier Universitaire de Nice
Numerous factors, both individual and environmental, can influence aging, an individual's health, and their functional status.
However, the understanding of the combined impact of lifestyle-related exposures (e.g., physical activity, diet, sleep) (personal external exposome), exposures to pollutants (environmental external exposome), and their biological responses (internal exposome)-in other words, the impact of the "exposome" on healthy aging-remains limited, particularly in characterizing the molecular mechanisms associated with these interactions.
Exposome approaches identifying key exposures and molecular mechanisms could lead to a better understanding of how the environment, interacting with health behaviors, can affect functional status.
Thus, the objective of this study is i) to evaluate the links between the external exposome, the internal exposome and the health of older and aging individuals, and ii) to identify biological markers associated with a vulnerable health status in older and aging individuals.
Studieöversikt
Status
Har inte rekryterat ännu
Betingelser
Intervention / Behandling
Studietyp
Interventionell
Inskrivning (Beräknad)
400
Fas
- Inte tillämpbar
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studiekontakt
- Namn: Virginie PIOVANO
- E-post: piovano.v@chu-nice.fr
Studera Kontakt Backup
- Namn: Olivier GUERIN, PROFESSOR
- Telefonnummer: 0492034194
- E-post: guerin.o@chu-nice.fr
Studieorter
-
-
-
Nice, Frankrike
- CHU de Nice - Hopital de Cimiez
-
Huvudutredare:
- Olivier GUERIN, Pr
-
Kontakt:
- Olivier GUERIN, Pr
- Telefonnummer: 0492034194
- E-post: guerin.o@chu-nice.fr
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Ja
Beskrivning
Inclusion Criteria:
- Aged 55 or over
- Affiliated with or beneficiaries of a social security scheme
- Signed the informed consent form •-Persons residing in one of the following municipalities : Antibes, Le Bar-sur-Loup, Berre-les-Alpes, Beuil, Blausasc, Breil-sur-Roya, Cabris, Cannes, Carros, Clans, Contes, Drap, L'Escarène, Escragnolles, Fontan, La Gaude, Gilette, Grasse, Lantosque, Levens, Nice, Peillon, Peymeinade, Saint-André-de-la-Roche, Saint-Etienne-de-Tinée, Sospel, Tourrettes-sur-Loup, Vence, Tende
Exclusion Criteria:
- patients currently undergoing intensive drug treatment, including chemotherapy
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Övrig
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Övrig: Exposome assessment
|
Visit 1: blood sample, questionnaires on the personal exposome (lifestyle habits (e.g., physical activity, diet, stress) and social characteristics and health status) | ii) Outpatient assessment: wearing a silicone bracelet for 7 days to measure external environmental exposure to pollutants and quantify physical activity | iii) Visit 2: 1-year follow-up of health status
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Frailty (health measure)
Tidsram: at baseline and 12 months later
|
Frailty is assessed using the Groningen Frailty Indicator.
The scale comprises 15 items.
The total score ranges from 0 to 25, with a higher score being worse.
|
at baseline and 12 months later
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Functional and health status
Tidsram: at baseline and 1 year
|
Disease presence : : Presence (yes/no) of chronic disease
|
at baseline and 1 year
|
|
Physical functional capacities (health measure)
Tidsram: at baseline and at 12 months
|
Physical functional capacities are assessed using the Short Physical Performance Battery which assess balance, walking capacities and strength via a sit to stand test
|
at baseline and at 12 months
|
|
Quality of life (health measure)
Tidsram: at baseline and 12 months
|
Quality of life is assessed using the SF-12 questionnaire.
The scale comprises 12 items.
|
at baseline and 12 months
|
|
Autonomy (health measure)
Tidsram: at baseline and 12 months
|
Autonomy is assessed using the WHOQOL-OLD-AUT questionnaire.
The scale comprises 4 items.
The total score ranges from 4 to 20, with a higher score being better.
|
at baseline and 12 months
|
|
Comorbidity (health measure)
Tidsram: at baseline and 12 months
|
Comorbidity is assessed using the Charlson Index which counts the number of comorbidities.
Higher score means greater number of comorbidities and therefore a poorer health.
|
at baseline and 12 months
|
|
Pollutant metabolites (internal exposome/biological measure)
Tidsram: at baseline.
|
Presence in the blood metabolome of molecules directly associated with pollutants (initial or biotransformed compounds).
This outcome will be obtained through a metabolomic analysis by very high-resolution mass spectrometry (consisting of the analysis of all small organic molecules (or metabolites)) performed on blood samples taken by a blood sampling.
|
at baseline.
|
|
DNA and telomere damage (internal exposome/biological measure)
Tidsram: at baseline.
|
DNA damage will be obtained through epigenetic analysis by studying miRNAs.
|
at baseline.
|
|
exposure to air pollutants (external environmental exposome measure)
Tidsram: at baseline
|
characteristics in terms of air pollution of the living space (quantity of fine particulate matter (PM), ozone (O3), nitrogen dioxide (NO2), or sulfur dioxide (SO2))
|
at baseline
|
|
exposure to pesticides, hydrocarbons, plastics, flame retardant pollutants (external environmental exposome measure)
Tidsram: at baseline
|
the exposure will be obtained through a silicone bracelet worn for 7 days by the participant, which will allow the measure of all exposures in the person's daily life.
|
at baseline
|
|
Smoking habits (external personal exposome measure)
Tidsram: at baseline.
|
smoking/non-smoking status identified via questionnaire.
|
at baseline.
|
|
Alcohol habits (external personal exposome measure)
Tidsram: at baseline
|
consumption volume identified via questionnaire.
|
at baseline
|
|
Self-reported physical activity habits (external personal exposome measure)
Tidsram: at baseline
|
volume of physical activity practice over a week identified via questionnaire.
|
at baseline
|
|
Objective-measured physical activity habits (external personal exposome measure)
Tidsram: at baseline
|
volume of physical activity practice over a week identified via actigraphy.
|
at baseline
|
|
Socioeconomic characteristic (external personal exposome measure)
Tidsram: at baseline
|
level of study identified via questionnaire.
|
at baseline
|
|
Socioeconomic characteristic (external personal exposome measure)
Tidsram: at baseline
|
socio-professional category identified via questionnaire.
|
at baseline
|
|
Psychological health (external personal exposome measure)
Tidsram: at baseline
|
anxiety assessed using the Hospital Anxiety and Depression Scale (HAD).
The scale comprises 14 items.
The total score ranges from 0 to 21, with a higher score being worse.
|
at baseline
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Beräknad)
1 september 2030
Primärt slutförande (Beräknad)
1 september 2031
Avslutad studie (Beräknad)
1 september 2031
Studieregistreringsdatum
Först inskickad
11 juni 2026
Först inskickad som uppfyllde QC-kriterierna
24 juni 2026
Första postat (Faktisk)
1 juli 2026
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
1 juli 2026
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
24 juni 2026
Senast verifierad
1 juni 2026
Mer information
Termer relaterade till denna studie
Andra studie-ID-nummer
- 25-PP-25
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Nej
Studerar en amerikansk FDA-reglerad produktprodukt
Nej
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .